EXEL : Analysis & Opinions
March 6, 2015Exelixis was the worst-performing biotech company, with its shares collapsing after its COMET-1 study showed that its cancer ...
November 3, 2011Dendreon's Provenge continues to shape up as a major disappointment.
June 7, 2011Investors shouldn't be spooked by the normal post-ASCO sell-off
November 18, 2009Fourth healthcare stocks that have brushed aside any potential adversity that could arise from future legislation for the ...